JNJ-63709178 / Genmab, J&J  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JNJ-63709178 / J&J, Genmab
NCT02715011: Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Checkmark Clinical hold for the treatment of AML
Sep 2016 - Sep 2016: Clinical hold for the treatment of AML
Completed
1
62
Europe, US
JNJ-63709178
Janssen Research & Development, LLC
Leukemia, Myeloid, Acute
03/21
03/21

Download Options